Traders Purchase Large Volume of Vanda Pharmaceuticals Call Options (VNDA)
Vanda Pharmaceuticals (NASDAQ:VNDA) was the target of unusually large options trading activity on Wednesday. Traders acquired 21,449 call options on the company, AR Network reports. This is an increase of 910% compared to the typical daily volume of 2,123 call options.
Several analysts have recently commented on the stock. Analysts at Piper Jaffray initiated coverage on shares of Vanda Pharmaceuticals in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $21.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Vanda Pharmaceuticals from $13.00 to $20.00 in a research note to investors on Friday, November 15th. They now have a “buy” rating on the stock. Finally, analysts at JMP Securities set a $23.00 price target on shares of Vanda Pharmaceuticals in a research note to investors on Friday, November 15th. They now have a “market outperform” rating on the stock. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $18.68.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) remained flat at $12.16 during trading on Thursday. The stock had a trading volume of 78,404 shares. Vanda Pharmaceuticals has a 1-year low of $3.57 and a 1-year high of $15.65. The stock has a 50-day moving average of $11.23 and a 200-day moving average of $10.36. The company’s market cap is $403.6 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings data on Thursday, November 7th. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.30) by $0.13. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.45 million. During the same quarter last year, the company posted ($0.19) earnings per share. Vanda Pharmaceuticals’s revenue was up 4.8% compared to the same quarter last year. Analysts expect that Vanda Pharmaceuticals will post $-0.62 EPS for the current fiscal year.
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.